1. Home
  2. SILO vs PRPO Comparison

SILO vs PRPO Comparison

Compare SILO & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silo Pharma Inc.

SILO

Silo Pharma Inc.

HOLD

Current Price

$0.33

Market Cap

5.1M

ML Signal

HOLD

Logo Precipio Inc.

PRPO

Precipio Inc.

N/A

Current Price

$23.00

Market Cap

32.4M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
SILO
PRPO
Founded
2010
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Laboratory Analytical Instruments
Sector
Consumer Discretionary
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
5.1M
32.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SILO
PRPO
Price
$0.33
$23.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
174.4K
7.7K
Earning Date
11-13-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$72,102.00
$22,800,000.00
Revenue This Year
$1.86
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
30.95
52 Week Low
$0.33
$3.90
52 Week High
$3.37
$28.50

Technical Indicators

Market Signals
Indicator
SILO
PRPO
Relative Strength Index (RSI) 34.00 47.46
Support Level $0.37 $22.40
Resistance Level $0.43 $24.60
Average True Range (ATR) 0.03 1.27
MACD -0.01 -0.23
Stochastic Oscillator 2.15 27.65

Price Performance

Historical Comparison
SILO
PRPO

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Share on Social Networks: